NAUGATUCK CHAMBER
  • Directory
  • Why Join?
  • Events & Sponsors
  • Duck Race & Festival
  • Job Board
  • About Us
  • Member Login
  • Directory
  • Why Join?
  • Events & Sponsors
  • Duck Race & Festival
  • Job Board
  • About Us
  • Member Login
  • Back
  • Membership
  • Member Benefits
  • Ribbon Cuttings
  • Member Login
  • Newsletter
  • Back
  • Sponsorships
  • Annual Dibble Award
  • Photo Gallery
  • Chamber Events
  • Community Calendar
  • Back
  • About Us
  • Southbury Chamber
  • Waterbury Regional Chamber
  • Watertown Oakville Chamber
  • 2024-25 Chamber Member Business Directory

Stemline Therapeutics, Inc.

  • Home

Stemline Therapeutics, Inc.

 
Search | Advanced Search | New Members | Coupons and Discounts | All Categories
 
 
 
 
 
 
 
Related Categories
Industrial & Manufacturing - Manufacturers
 
 
 
Industrial & Manufacturing >> Industrial & Manufacturing - Manufacturers

Stemline Therapeutics, Inc.

750 Lexington Avenue
New York, NY 10022 | View on Google Maps
Ms. Jill Sturges Ms. Jill Sturges
(646) 502-2310

Visit Site

Stemline Therapeutics, a part of the Menarini Group, is focused on the development and commercialization of novel oncology therapeutics.

The goal of our dedicated team of scientists, specialists, researchers, and developers is to build a leading biopharmaceutical company focused on improving the lives of cancer patients by developing and commercializing novel first-in-class therapeutics.

ELZONRIS® (tagraxofusp), a targeted therapy directed to CD123, is FDA-approved and commercially available in the U.S. for the treatment of adult and pediatric patients, two years or older, with blastic plasmacytoid dendritic cell neoplasm (BPDCN). In Europe, the European Medicines Agency (EMA) approved ELZONRIS in January 2021. ELZONRIS is also being evaluated in clinical trials in additional indications including acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML), and myelofibrosis (MF).

ORSERDU (elacestrant) is a selective estrogen receptor degrader (SERD) FDA approved for the treatment of postmenopausal women or adult men, with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy. Studies completed to date, including the positive results from the pivotal EMERALD trial, indicate that the compound has the potential for use as a single agent or in combination with other therapies for the treatment of breast cancer. Indeed, ORSERDU is the first FDA approved oral SERD to show positive results in a pivotal, Phase III trial as a monotherapy versus standard of care for the treatment of ER+/ HER2- advanced or metastatic breast cancer.

Stemline is headquartered in New York City.

Member Since: 2023
Send a message to:

  Stemline Therapeutics, Inc.  

Your Name:
Your Email:
Subject:
   
Message:
   
 

 (Date: 5/19/2025)
 

 

Upcoming Events

Master Your Membership May 2025

May 22, 20258:30 AM - 9:30 AM

Naugatuck Wake Up Your Business May 2025

May 23, 20258:00 AM - 9:00 AM

Duck Race and Festival 2025- Naugatuck Chamber

Jun 01, 202511:00 AM - 4:00 PM

Out for Health - June @ The Village at East Farms

Jun 05, 20257:30 AM - 9:00 AM

Watertown Oakville June Wake Up Your Business

Jun 06, 20258:00 AM - 9:00 AM

Young Professionals Karaoke Happy Hour - Jameson Pub

Jun 12, 20255:30 PM - 7:00 PM

View All Events
Naugatuck Chamber  All Rights Reserved.
270 Church Street, Naugatuck, CT 06770
Phone: (203) 729-4511 Fax: (203) 729-4512 | info@naugatuckchamber.com | sitemap
Terms and Conditions/Privacy Policy
Picture
  • Membership
  • Member Benefits
  • Ribbon Cuttings
  • Member Login
  • Newsletter
  • Sponsorships
  • Annual Dibble Award
  • Photo Gallery
  • Chamber Events
  • Community Calendar
  • About Us
  • Southbury Chamber
  • Waterbury Regional Chamber
  • Watertown Oakville Chamber
  • 2024-25 Chamber Member Business Directory